NCT00558103

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 163 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumors overexpress the ErbB2 protein. There is also an Open-label pazopanib arm to this study designed to test whether pazopanib given alone and lapatinib given alone would be safe and effective to treat patients with inflammatory breast cancer.

Conditions

• Neoplasms, Breast

Interventions

Type	Name	Description
DRUG	lapatinib	Oral administration
DRUG	Pazopanib	Oral administration

Timeline

• Start date: 2007-12-01
• Primary completion: 2011-05-01
• Completion: 2011-12-01
• First posted: 2007-11-14
• Last updated: 2013-02-04
• Results posted: 2012-07-18

Locations

126 sites across 28 countries: United States, Australia, Belgium, Canada, Chile, China, Czechia, Egypt, France, Germany, Greece, Hong Kong, Israel, Italy, Morocco, Pakistan, Peru, Philippines, Romania, Russia, Singapore, South Korea, Spain, Taiwan, Thailand, Tunisia, Turkey (Türkiye), United Kingdom